CN115385887B - 一种铵盐离子液体催化环合反应制备伊索克酸的方法 - Google Patents
一种铵盐离子液体催化环合反应制备伊索克酸的方法 Download PDFInfo
- Publication number
- CN115385887B CN115385887B CN202210637583.3A CN202210637583A CN115385887B CN 115385887 B CN115385887 B CN 115385887B CN 202210637583 A CN202210637583 A CN 202210637583A CN 115385887 B CN115385887 B CN 115385887B
- Authority
- CN
- China
- Prior art keywords
- ionic liquid
- parts
- ethyl acetate
- ammonium salt
- reaction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000002608 ionic liquid Substances 0.000 title claims abstract description 45
- 238000000034 method Methods 0.000 title claims abstract description 31
- 150000003863 ammonium salts Chemical class 0.000 title claims abstract description 25
- ITGSCCPVERXFGN-UHFFFAOYSA-N isoxadifen Chemical compound C1C(C(=O)O)=NOC1(C=1C=CC=CC=1)C1=CC=CC=C1 ITGSCCPVERXFGN-UHFFFAOYSA-N 0.000 title claims abstract description 19
- 238000007363 ring formation reaction Methods 0.000 title claims abstract description 14
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims abstract description 99
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims abstract description 27
- 238000006243 chemical reaction Methods 0.000 claims abstract description 19
- 239000012074 organic phase Substances 0.000 claims abstract description 16
- DLYUQMMRRRQYAE-UHFFFAOYSA-N tetraphosphorus decaoxide Chemical compound O1P(O2)(=O)OP3(=O)OP1(=O)OP2(=O)O3 DLYUQMMRRRQYAE-UHFFFAOYSA-N 0.000 claims abstract description 16
- 239000012043 crude product Substances 0.000 claims abstract description 15
- 239000002904 solvent Substances 0.000 claims abstract description 14
- 239000002253 acid Substances 0.000 claims abstract description 12
- 238000001914 filtration Methods 0.000 claims abstract description 10
- BCYWXPITXHFIQM-UHFFFAOYSA-N 2-[[4-(carboxymethyl)phenoxy]methyl]benzoic acid Chemical compound C1=CC(CC(=O)O)=CC=C1OCC1=CC=CC=C1C(O)=O BCYWXPITXHFIQM-UHFFFAOYSA-N 0.000 claims abstract description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 8
- 238000010438 heat treatment Methods 0.000 claims abstract description 7
- 239000000706 filtrate Substances 0.000 claims abstract description 6
- 108010009736 Protein Hydrolysates Proteins 0.000 claims abstract description 3
- 238000001704 evaporation Methods 0.000 claims abstract description 3
- 238000010791 quenching Methods 0.000 claims abstract description 3
- 230000000171 quenching effect Effects 0.000 claims abstract description 3
- 238000007670 refining Methods 0.000 claims abstract description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 16
- 238000003756 stirring Methods 0.000 claims description 9
- 229910052757 nitrogen Inorganic materials 0.000 claims description 8
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 6
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 claims description 6
- 238000006798 ring closing metathesis reaction Methods 0.000 claims description 6
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 claims description 6
- 229910021578 Iron(III) chloride Inorganic materials 0.000 claims description 5
- RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 claims description 5
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 claims description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 4
- 125000000129 anionic group Chemical group 0.000 claims description 4
- 238000001035 drying Methods 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- KBZUICKSJWHZIF-UHFFFAOYSA-N n,n-diphenylaniline;hydrochloride Chemical compound [Cl-].C1=CC=CC=C1[NH+](C=1C=CC=CC=1)C1=CC=CC=C1 KBZUICKSJWHZIF-UHFFFAOYSA-N 0.000 claims description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 3
- ILWRPSCZWQJDMK-UHFFFAOYSA-N triethylazanium;chloride Chemical compound Cl.CCN(CC)CC ILWRPSCZWQJDMK-UHFFFAOYSA-N 0.000 claims description 3
- XOKPOPWYLRKXEA-UHFFFAOYSA-N trihexylazanium;chloride Chemical compound Cl.CCCCCCN(CCCCCC)CCCCCC XOKPOPWYLRKXEA-UHFFFAOYSA-N 0.000 claims description 3
- 235000005074 zinc chloride Nutrition 0.000 claims description 3
- 239000011592 zinc chloride Substances 0.000 claims description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 2
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 2
- 230000035484 reaction time Effects 0.000 claims 1
- 239000003054 catalyst Substances 0.000 abstract description 6
- 239000002351 wastewater Substances 0.000 abstract description 5
- 230000000694 effects Effects 0.000 abstract description 4
- 238000004519 manufacturing process Methods 0.000 abstract description 4
- 230000003197 catalytic effect Effects 0.000 abstract description 3
- 230000015572 biosynthetic process Effects 0.000 abstract description 2
- 239000002994 raw material Substances 0.000 abstract description 2
- 238000003786 synthesis reaction Methods 0.000 abstract description 2
- 239000012024 dehydrating agents Substances 0.000 abstract 1
- WCGUUGGRBIKTOS-GPOJBZKASA-N (3beta)-3-hydroxyurs-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C WCGUUGGRBIKTOS-GPOJBZKASA-N 0.000 description 11
- 229940096998 ursolic acid Drugs 0.000 description 11
- PLSAJKYPRJGMHO-UHFFFAOYSA-N ursolic acid Natural products CC1CCC2(CCC3(C)C(C=CC4C5(C)CCC(O)C(C)(C)C5CCC34C)C2C1C)C(=O)O PLSAJKYPRJGMHO-UHFFFAOYSA-N 0.000 description 11
- 239000007787 solid Substances 0.000 description 9
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 229920000137 polyphosphoric acid Polymers 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- -1 methoxy, methyl Chemical group 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 239000002841 Lewis acid Substances 0.000 description 4
- 229960000583 acetic acid Drugs 0.000 description 4
- 230000000052 comparative effect Effects 0.000 description 4
- 239000012362 glacial acetic acid Substances 0.000 description 4
- 229910052739 hydrogen Inorganic materials 0.000 description 4
- 239000001257 hydrogen Substances 0.000 description 4
- 150000007517 lewis acids Chemical class 0.000 description 4
- 239000000413 hydrolysate Substances 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- VNICJHGMMYPVLC-UHFFFAOYSA-K aluminum;n,n-diethylethanamine;trichloride Chemical compound [Al+3].[Cl-].[Cl-].[Cl-].CCN(CC)CC VNICJHGMMYPVLC-UHFFFAOYSA-K 0.000 description 2
- 150000001450 anions Chemical class 0.000 description 2
- 239000000043 antiallergic agent Substances 0.000 description 2
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 238000006555 catalytic reaction Methods 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 2
- DIAIBWNEUYXDNL-UHFFFAOYSA-N n,n-dihexylhexan-1-amine Chemical compound CCCCCCN(CCCCCC)CCCCCC DIAIBWNEUYXDNL-UHFFFAOYSA-N 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 238000001291 vacuum drying Methods 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 1
- HVRLZEKDTUEKQH-NOILCQHBSA-N Olopatadine hydrochloride Chemical compound Cl.C1OC2=CC=C(CC(O)=O)C=C2C(=C/CCN(C)C)\C2=CC=CC=C21 HVRLZEKDTUEKQH-NOILCQHBSA-N 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 150000001449 anionic compounds Chemical class 0.000 description 1
- 229940114079 arachidonic acid Drugs 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000001460 carbon-13 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 238000007036 catalytic synthesis reaction Methods 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000001808 coupling effect Effects 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- VILAVOFMIJHSJA-UHFFFAOYSA-N dicarbon monoxide Chemical group [C]=C=O VILAVOFMIJHSJA-UHFFFAOYSA-N 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
- 229910001412 inorganic anion Inorganic materials 0.000 description 1
- 150000002617 leukotrienes Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007830 nerve conduction Effects 0.000 description 1
- 229960004114 olopatadine Drugs 0.000 description 1
- JBIMVDZLSHOPLA-LSCVHKIXSA-N olopatadine Chemical compound C1OC2=CC=C(CC(O)=O)C=C2C(=C/CCN(C)C)\C2=CC=CC=C21 JBIMVDZLSHOPLA-LSCVHKIXSA-N 0.000 description 1
- 229960003139 olopatadine hydrochloride Drugs 0.000 description 1
- 150000002891 organic anions Chemical class 0.000 description 1
- 150000002892 organic cations Chemical class 0.000 description 1
- 230000010355 oscillation Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000020477 pH reduction Effects 0.000 description 1
- 208000035824 paresthesia Diseases 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- RZWIIPASKMUIAC-VQTJNVASSA-N thromboxane Chemical compound CCCCCCCC[C@H]1OCCC[C@@H]1CCCCCCC RZWIIPASKMUIAC-VQTJNVASSA-N 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D313/00—Heterocyclic compounds containing rings of more than six members having one oxygen atom as the only ring hetero atom
- C07D313/02—Seven-membered rings
- C07D313/06—Seven-membered rings condensed with carbocyclic rings or ring systems
- C07D313/10—Seven-membered rings condensed with carbocyclic rings or ring systems condensed with two six-membered rings
- C07D313/12—[b,e]-condensed
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J31/00—Catalysts comprising hydrides, coordination complexes or organic compounds
- B01J31/02—Catalysts comprising hydrides, coordination complexes or organic compounds containing organic compounds or metal hydrides
- B01J31/0277—Catalysts comprising hydrides, coordination complexes or organic compounds containing organic compounds or metal hydrides comprising ionic liquids, as components in catalyst systems or catalysts per se, the ionic liquid compounds being used in the molten state at the respective reaction temperature
- B01J31/0278—Catalysts comprising hydrides, coordination complexes or organic compounds containing organic compounds or metal hydrides comprising ionic liquids, as components in catalyst systems or catalysts per se, the ionic liquid compounds being used in the molten state at the respective reaction temperature containing nitrogen as cationic centre
- B01J31/0279—Catalysts comprising hydrides, coordination complexes or organic compounds containing organic compounds or metal hydrides comprising ionic liquids, as components in catalyst systems or catalysts per se, the ionic liquid compounds being used in the molten state at the respective reaction temperature containing nitrogen as cationic centre the cationic portion being acyclic or nitrogen being a substituent on a ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C209/00—Preparation of compounds containing amino groups bound to a carbon skeleton
- C07C209/68—Preparation of compounds containing amino groups bound to a carbon skeleton from amines, by reactions not involving amino groups, e.g. reduction of unsaturated amines, aromatisation, or substitution of the carbon skeleton
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2231/00—Catalytic reactions performed with catalysts classified in B01J31/00
- B01J2231/40—Substitution reactions at carbon centres, e.g. C-C or C-X, i.e. carbon-hetero atom, cross-coupling, C-H activation or ring-opening reactions
- B01J2231/42—Catalytic cross-coupling, i.e. connection of previously not connected C-atoms or C- and X-atoms without rearrangement
- B01J2231/4205—C-C cross-coupling, e.g. metal catalyzed or Friedel-Crafts type
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/54—Improvements relating to the production of bulk chemicals using solvents, e.g. supercritical solvents or ionic liquids
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Materials Engineering (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
本发明提供一种铵盐离子液体催化环合反应制备伊索克酸的方法,包括:按重量比,加入2‑[(4‑羧甲基苯氧基)甲基]苯甲酸2‑4份、五氧化二磷2‑8份、铵盐离子液体4‑12份和溶剂6‑14份,加热至30‑100℃,反应2‑10h;反应结束后,按重量比加入10‑60份水,淬灭离子液体后,过滤其水解产物,对滤液加入10‑30份乙酸乙酯,萃取三次,合并有机相,对有机相加入活性炭脱色,过滤活性炭,蒸除溶剂乙酸乙酯,得伊索克酸粗品;用乙酸乙酯溶解伊索克酸粗品,精制脱色,得伊索克酸。本发明方法以2‑[(4‑羧甲基苯氧基)甲基]苯甲酸为原料,五氧化二磷为脱水剂,铵盐离子液体为催化剂,具有合成工艺简单,催化剂活性高耐高温,催化条件温和,生产成本低,后处理废水较少等优点。
Description
技术领域
本发明涉及一种铵盐离子液体催化环合反应制备伊索克酸的方法,属于化学催化合成领域。
背景技术
离子液体(Ionic Liquids,ILs)是一种由有机阳离子和无机或者有机小分子阴离子组成的,在室温条件下呈现为液体状态的熔融盐物质。离子液体因其宽泛的温域,即在很宽的温域范围内能够很好的以稳定的熔融盐的形式存在;而且离子液体由于阴阳离子的可调节性,使得其在实际反应以及工业化中具有无限可能,同时离子液体也使其能够在反应中起到溶剂与催化剂的作用。离子液体中阳离子主要控制离子液体的极性,阴离子决定其催化性能,改变阳离子调整离子液体的极性可以达到产物与原料的直接分离,进而实现工业上的循环生产。
与传统的催化剂相比,以路易斯酸为无机阴离子合成路易斯酸盐离子液体,同时路易斯酸也因为其可控的酸碱性使得其对于路易斯酸类催化的反应具有无限可能。
伊索克酸是合成新型抗过敏药物盐酸奥洛他定的关键中间体。奥洛他定是由日本协和发酵公司开发并上市的口服抗过敏药,具有抗组腔作用,而且能抑制组脏、花生四烯酸、血栓素、白三烯等化学递质和速激肤类神经传导物质的释放,对慢性等麻痊、过敏性鼻炎、支气管哮喘、湿荡、皮炎等各种过敏性疾病具有良好疗效,具有良好的市场前景。
目前,国内制备伊索克酸均采用缩合、水解、酸化、环合四步反应,以及多次萃取和重结晶操作的传统工艺路线,繁琐的传统工艺流程决定了国产伊索克酸的成本高。特别是环化反应中多采取多聚磷酸与冰醋酸共同催化反应,造成其废水量大,生产成本高。
迄今为止,还未有文献报道利用铵盐离子液体作为催化剂,催化环合反应制备伊索克酸,探索一种简单、高效、低废制备伊索克酸的方法。
发明内容
本发明的目的在于提供一种铵盐离子液体催化环合反应制备伊索克酸的方法,本发明以更高效的铵盐离子液体作为催化剂,代替伊索克酸传统制备工艺中采用的多聚磷酸与冰醋酸,降低生产成本,减短反应周期,提高收率。
为解决上述技术问题,本发明提供如下技术方案:一种铵盐离子液体催化环合反应制备伊索克酸的方法,包括:
(1)环合:按重量比,加入2-[(4-羧甲基苯氧基)甲基]苯甲酸2-4份、五氧化二磷2-8份、铵盐离子液体4-12份和溶剂6-14份,加热至30-100℃反应2-10h;
(2)后处理:反应结束后,按重量比加入10-60份水,淬灭离子液体后,过滤其水解产物,对滤液加入10-30份乙酸乙酯,萃取三次,合并有机相,对有机相加入活性炭脱色,过滤活性炭,蒸除溶剂乙酸乙酯,得伊索克酸粗品;
(3)提纯:用乙酸乙酯溶解伊索克酸粗品,精制脱色,得伊索克酸。
本发明的优选技术方案中,在步骤(1)中,所述铵盐离子液体的结构如式(I)所示:
其中,R选自氢、苯基、苄基、甲氧基、甲基、乙基、丁基和己基中的一种,X-为ZnCl3-、FeCl4-、Br-、BF4-、PF6-和AlCl4-中的一种。
本发明的优选技术方案中,所述铵盐离子液体通过如下方法制备:
常温下,按摩尔比加入铵类盐酸盐8-12份和阴离子盐类6-14份,氮气保护下,加热搅拌或常温搅拌1-8h,反应结束后用乙酸乙酯洗涤,得铵盐离子液体。
本发明的优选技术方案中,所述铵类盐酸盐包括三苯基胺盐酸盐、三乙基胺盐酸盐和三己基胺盐酸盐中的一种;所述阴离子盐类包括氯化锌、无水氯化铝和氯化铁中的一种。
本发明的优选技术方案中,所述加热搅拌的温度为30-85℃,优选为45-65℃;加热搅拌或常温搅拌4-6h。
本发明的优选技术方案中,还包括干燥步骤,将铵盐离子液体置于真空干燥箱中干燥。
本发明的优选技术方案中,在步骤(1)中,所述反应温度为45-90℃,优选为65℃-85℃;反应3-9h,优选为4-8h。
本发明的优选技术方案中,在步骤(1)中,所述溶剂为二氯甲烷、四氢呋喃、乙酸乙酯、二甲基亚砜和N,N-二甲基甲酰胺中的一种,优选为乙酸乙酯。
本发明的优选技术方案中,在步骤(2)中,所述活性炭的用量为有机相重量的1-8%。
本发明的优选技术方案中,在步骤(3)中,所述乙酸乙酯的用量为伊索克酸粗品重量的3-8倍,在60-85℃下溶解。
与现有技术相比,本发明具有如下技术效果:
1、本发明采用铵盐离子液体作为催化剂,代替伊索克酸传统制备工艺中采用的多聚磷酸与冰醋酸,产生的废水量小,极大地降低生产成本,使工艺更加绿色环保。
2、本发明所用的铵盐离子液体,简单易制得,成本低,性质稳定,较传统制备工艺所用的多聚磷酸与冰醋酸污染性小,毒性低。
附图说明
图1为实施例4制备的伊索克酸的1H-NMR谱图;
图2为实施例4制备的伊索克酸的13C-NMR谱图;
图3为实施例4制备的伊索克酸的FT-IR图。
具体实施方式
下面结合说明书附图和具体实施例,进一步阐述本发明。这些实施例仅用于说明本发明而不用于限制本发明的范围。下面实施例中未注明具体条件的实验方法,通常按照本领域常规条件或按照制造厂商建议的条件。本领域的技术人员在发明的基础上所做的任何非实质性的变化及替换均属于本发明所要求保护的范围。
实施例1
本实施例提供一种三苯基铵氯化锌盐的制备方法,包括:
称量0.02mol三苯基胺盐酸盐(5.6358g)和0.02mol氯化锌(2.726g),氮气保护下,在45℃搅拌反应4h,得到白色固体,使用10ml乙酸乙酯洗涤三次,在真空干燥箱中干燥一夜,得8.036g白色粉末,产率为96.12%。
实施例2
本实施例提供一种三乙基铵氯化铝盐的制备方法,包括:
称量0.02mol三乙基胺盐酸盐(2.753g)和0.025mol无水氯化铝(3.3335g),在氮气保护下,常温搅拌3h,使用10ml乙酸乙酯洗涤三次,得5.995g黄色粘稠状溶液,产率为98.53%。
实施例3
本实施例提供一种三己基铵氯化铁盐的制备方法,包括:
称量0.02mol三己基胺盐酸盐(4.436g)、0.02mol氯化铁(3.244g)和18ml无水乙醇,氮气保护下,在65℃下搅拌7h,蒸除溶剂,使用10ml乙酸乙酯洗涤三次,真空干燥箱中干燥一夜,得7.480g棕色固体粉末,产率为97.42%。
实施例4
本实施例提供一种铵盐离子液体催化环合反应制备伊索克酸的方法,包括:
(1)环合:配制称量2-[(4-羧甲基苯氧基)甲基]苯甲酸5.7256g(0.02mol),五氧化二磷1.5g,实施例1制备的三苯基铵氯化锌盐离子液体4.1809g(0.01mol),乙酸乙酯30ml,氮气保护下在60℃保持回流4h。
(2)后处理:反应结束后加入75ml水,淬灭离子液体后,过滤其水解产物,对滤液加入70ml乙酸乙酯萃取三次,合并有机相。对有机相加入0.25g活性炭脱色,过滤活性炭后,蒸除溶剂乙酸乙酯,得到棕黄色固体伊索克酸粗品4.2864g。
(3)提纯:用18ml乙酸乙酯加热溶解伊索克酸粗品,重结晶精制脱色,得浅色固体粉末伊索克酸产品3.6078g,产率为67.24%。
通过图1-3可以看出,伊索克酸的核磁氢谱中,3.64ppm为羧基旁亚甲基单峰;而5.29ppm为三号位处与氧相连的亚甲基单峰,7.06ppm和7.08ppm为苯环三号位处上氢受到芳环上其他位置的原子的耦合作用而造成的dd裂分,12.43ppm处为羧基氢;在相应的碳谱中一共有16种不同化学环境的碳,196.60ppm处为羰基碳,174.76ppm处为羧基碳特征峰;红外谱图中3264cm-1处峰表明有羟基存在,1665cm-1处峰表明有羰基存在,这些都证明伊索克酸的成功合成。
实施例5
本实施例提供一种铵盐离子液体催化环合反应制备伊索克酸的方法,包括:
(1)环合:配制称量2-[(4-羧甲基苯氧基)甲基]苯甲酸5.7256g(0.02mol),五氧化二磷2.5g,实施例2制备的三乙基铵氯化铝盐离子液体0.02mol(6.0865g),乙酸乙酯30ml,氮气保护下在55℃保持回流7.5h。
(2)后处理:反应结束后加入75ml水,淬灭离子液体后,过滤其水解产物,对滤液加入75ml乙酸乙酯萃取三次,合并有机相。对有机相加入0.25g活性炭脱色,过滤活性炭后,蒸除溶剂乙酸乙酯,得到棕黄色固体伊索克酸粗品4.3324g。
(3)提纯:用18ml乙酸乙酯加热溶解伊索克酸粗品,重结晶精制脱色,得浅色固体粉末伊索克酸产品3.0568g,产率为56.97%。经红外及核磁检测,本实施例同样能够成功合成伊索克酸。
实施例6
本实施例提供一种铵盐离子液体催化环合反应制备伊索克酸的方法,包括:
(1)环合:配制称量2-[(4-羧甲基苯氧基)甲基]苯甲酸5.7256g(0.02mol),五氧化二磷1.5g,实施例3制备的三己基铵氯化铁盐离子液体7.6766g(0.02mol),乙酸乙酯30ml,氮气保护下在55℃保持回流7.5h。
(2)后处理:反应结束后加入80ml水,淬灭离子液体后,过滤其水解产物,对滤液加入70ml乙酸乙酯萃取三次,合并有机相。对有机相加入0.25g活性炭脱色,过滤活性炭后,蒸除溶剂乙酸乙酯,得到棕黄色固体伊索克酸粗品4.2478g。
(3)提纯:用20ml乙酸乙酯加热溶解伊索克酸粗品,重结晶精制脱色,得浅色固体粉末伊索克酸产品3.4589g,产率为64.46%。经红外及核磁检测,本实施例同样能够成功合成伊索克酸。
对比例1
本对比例提供一种多聚磷酸催化环合反应制备伊索克酸的方法,包括:
(1)环合:配制称量2-[(4-羧甲基苯氧基)甲基]苯甲酸5.7256g(0.02mol),冰醋酸11.451g,五氧化二磷0.318g,多聚磷酸24.174g(0.07mol),水浴加热在65℃搅拌反应5h。
(2)后处理:反应结束后加入150ml水,稀释反应液。稀释完毕后,通冰盐水冷却到0-5℃,保温2h,过滤,得伊索克酸粗品4.1566g。
(3)提纯:用20ml乙酸乙酯加热溶解伊索克酸粗品,重结晶精制脱色,得浅色固体粉末伊索克酸产品3.5791g,产率为66.71%。
将实施例5与对比例1比较,对比例1多聚磷酸传统工艺中,由于体系粘稠,搅拌比较困难,另外废水量相比于实施例5离子液体催化工艺较多,处理成本高,环保压力大。
表1两种工艺中废水量的对比
Claims (9)
1.一种铵盐离子液体催化环合反应制备伊索克酸的方法,其特征在于,包括:
(1)环合:按重量比,加入2-[(4-羧甲基苯氧基)甲基]苯甲酸2-4份、五氧化二磷2-8份、铵盐离子液体4-12份和溶剂6-14份,加热至30-100℃反应2-10h;
(2)后处理:反应结束后,按重量比加入10-60份水,淬灭离子液体后,过滤其水解产物,对滤液加入10-30份乙酸乙酯,萃取三次,合并有机相,对有机相加入活性炭脱色,过滤活性炭,蒸除溶剂乙酸乙酯,得伊索克酸粗品;
(3)提纯:用乙酸乙酯溶解伊索克酸粗品,精制脱色,得伊索克酸;
所述铵盐离子液体的结构如式(I)所示:
其中,R选自苯基、乙基、和己基中的一种,X-为ZnCl3-、FeCl4-、和AlCl4-中的一种;
所述溶剂为二氯甲烷、四氢呋喃、乙酸乙酯、二甲基亚砜和N,N-二甲基甲酰胺中的一种。
2.根据权利要求1所述的方法,其特征在于,所述铵盐离子液体通过如下方法制备:
常温下,按摩尔比加入铵类盐酸盐8-12份和阴离子盐类6-14份,氮气保护下,加热搅拌或常温搅拌1-8h,反应结束后用乙酸乙酯洗涤,得铵盐离子液体。
3.根据权利要求2所述的方法,其特征在于,所述铵类盐酸盐选自三苯基胺盐酸盐、三乙基胺盐酸盐和三己基胺盐酸盐中的一种;所述阴离子盐类选自氯化锌、无水氯化铝和氯化铁中的一种。
4.根据权利要求2所述的方法,其特征在于,所述加热搅拌的温度为30-85℃,搅拌时间为4-6h。
5.根据权利要求4所述的方法,所述加热搅拌的温度为45-65℃。
6.根据权利要求2所述的方法,其特征在于,还包括干燥步骤,将铵盐离子液体置于真空干燥箱中干燥。
7.根据权利要求1所述的方法,其特征在于,在步骤(1)中,所述反应温度为45-90℃,反应时间为3-9h。
8.根据权利要求7所述的方法,反应温度为65-85℃。
9.根据权利要求1所述的方法,其特征在于,在步骤(1)中,所述溶剂为乙酸乙酯。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210637583.3A CN115385887B (zh) | 2022-06-08 | 2022-06-08 | 一种铵盐离子液体催化环合反应制备伊索克酸的方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210637583.3A CN115385887B (zh) | 2022-06-08 | 2022-06-08 | 一种铵盐离子液体催化环合反应制备伊索克酸的方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN115385887A CN115385887A (zh) | 2022-11-25 |
CN115385887B true CN115385887B (zh) | 2024-01-23 |
Family
ID=84115905
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210637583.3A Active CN115385887B (zh) | 2022-06-08 | 2022-06-08 | 一种铵盐离子液体催化环合反应制备伊索克酸的方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN115385887B (zh) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006120010A2 (de) * | 2005-05-12 | 2006-11-16 | Merckle Gmbh | Dibenzocycloheptanverbindungen und pharmazeutische mittel, welche diese verbindungen enthalten |
EP2206534A1 (de) * | 2008-10-09 | 2010-07-14 | c-a-i-r biosciences GmbH | Dibenzocycloheptanonderivate und pharmazeutische Mittel, welche diese Verbindungen enthalten |
CN102241579A (zh) * | 2011-07-07 | 2011-11-16 | 辽宁石油化工大学 | 一种蒽醌的合成方法 |
CN102838582A (zh) * | 2012-09-19 | 2012-12-26 | 湖州恒远生物化学技术有限公司 | 一种伊索克酸的制备方法 |
CN110698451A (zh) * | 2019-10-29 | 2020-01-17 | 山东诚汇双达药业有限公司 | 取代二苯并[ b,e ]硫(氧)杂七环-11(6H)-酮类化合物及其制备方法 |
-
2022
- 2022-06-08 CN CN202210637583.3A patent/CN115385887B/zh active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006120010A2 (de) * | 2005-05-12 | 2006-11-16 | Merckle Gmbh | Dibenzocycloheptanverbindungen und pharmazeutische mittel, welche diese verbindungen enthalten |
EP2206534A1 (de) * | 2008-10-09 | 2010-07-14 | c-a-i-r biosciences GmbH | Dibenzocycloheptanonderivate und pharmazeutische Mittel, welche diese Verbindungen enthalten |
CN102241579A (zh) * | 2011-07-07 | 2011-11-16 | 辽宁石油化工大学 | 一种蒽醌的合成方法 |
CN102838582A (zh) * | 2012-09-19 | 2012-12-26 | 湖州恒远生物化学技术有限公司 | 一种伊索克酸的制备方法 |
CN110698451A (zh) * | 2019-10-29 | 2020-01-17 | 山东诚汇双达药业有限公司 | 取代二苯并[ b,e ]硫(氧)杂七环-11(6H)-酮类化合物及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN115385887A (zh) | 2022-11-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN111848630A (zh) | 基于炔基取代的氮杂对亚甲基苯醌制备吡咯并[1,2-a]吲哚类化合物的方法 | |
CN103613478B (zh) | 一种α-羟基羰基化合物的合成方法 | |
CN114292231B (zh) | 一种2-甲基-8-取代基-喹啉及其制备方法 | |
CN109651291B (zh) | 一种多取代萘并[1,2-d]噻唑及衍生物及其合成方法 | |
IL34897A (en) | History of tetrahydropyridoxylethane, mixtures containing them and their preparation | |
CN115385887B (zh) | 一种铵盐离子液体催化环合反应制备伊索克酸的方法 | |
CN105541773B (zh) | 一种3,4-二氢-4-芳基香豆素类化合物的制备方法 | |
CN108558778B (zh) | 二氢喹唑啉酮类化合物及其制备方法 | |
CN105820174A (zh) | 一种多取代噻吩并吲哚衍生物的制备方法 | |
JP2010254693A (ja) | 置換された1,4−キノンメチドの製造方法 | |
CN110256451B (zh) | 一种苯并呋喃并[2,3-b]喹啉衍生物的合成方法 | |
WO2023197384A1 (zh) | 一种铜催化一锅法制备大麻酚的方法 | |
CN102336763B (zh) | 一种吡喃香豆素衍生物的合成方法 | |
CN108503812B (zh) | 利用含邻苯二胺基的非对称铝配合物催化己内酯聚合的方法 | |
CN108264449B (zh) | 一种2,6-二乙基-4-甲基苯酚的制备方法 | |
CN102731469B (zh) | 一种高纯度1,4-二氧六环-2-酮的制备方法 | |
CN112979648B (zh) | 一种γ-咔啉衍生物的合成方法 | |
Vahdat | An green and efficient one-pot synthesis of coumarin derivatives catalyzed by cerium (IV) triflate at room temperature | |
CN115197135B (zh) | 一种锌催化制备多取代喹啉化合物的方法 | |
CN111377980B (zh) | 一种中间体双乙酰基二茂铁的合成方法 | |
CN110156676B (zh) | 一种3,4-二氢喹啉-2(1h)-酮类衍生物及其制备方法与应用 | |
CN101974578A (zh) | 一种复合酶催化水解制备喹诺酮类羧酸中间体的方法 | |
CN111087356B (zh) | 一种艾托莫德的制备方法 | |
CN114349751A (zh) | 一种6,7-二氢-5h-吡咯并吡啶的制备方法 | |
CN117964553A (zh) | 一种喹啉-n-氧化物类化合物选择性合成2-酰氨基喹啉-n-氧化物类化合物的方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |